RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Rating of “Hold” from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus recommendation of “Hold” by the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.56.

A number of research firms have commented on RAPT. Wells Fargo & Company decreased their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. UBS Group reduced their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. Finally, HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, December 26th.

RAPT Therapeutics Trading Up 2.5 %

Shares of RAPT opened at $1.67 on Friday. The company’s 50-day moving average price is $1.49 and its 200 day moving average price is $2.12. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $27.35. The firm has a market cap of $58.38 million, a P/E ratio of -0.60 and a beta of 0.07.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Equities research analysts forecast that RAPT Therapeutics will post -2.86 earnings per share for the current year.

Institutional Trading of RAPT Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its position in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares in the last quarter. Barclays PLC lifted its stake in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares during the last quarter. Readystate Asset Management LP acquired a new position in RAPT Therapeutics in the third quarter valued at approximately $36,000. Los Angeles Capital Management LLC increased its stake in RAPT Therapeutics by 138.1% in the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after purchasing an additional 116,853 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in RAPT Therapeutics by 244.7% during the third quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock worth $179,000 after purchasing an additional 63,235 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.